The First Issue of the WMO Arctic Ozone Bulletin for the 2015/16 Winter/Spring Season
February 3, 2016All Eyes were on Industry to Stop Ozone Depletion. Same Goes for Climate Change
February 3, 2016Report Maps the Qualitative Impact of Various Market Factors on Market Segments and Geographies Non-melanoma skin cancers develop in the outermost layer of skin, known as epidermis. It is caused by increased exposure of genetic mutations, UV rays and ozone layer depletion. Non-melanoma skin cancer is mainly classified into two types. They are basal cell carcinoma and squamous cell carcinoma. Basal cell carcinoma is one of the most common types of skin cancers. It accounts about 70% of all skin cancers.
Basal cell carcinoma starts underneath of the epidermis. Basal cell carcinoma usually appears as a red or pink lump. It usually develops on ears, face and neck. Squamous cell carcinoma accounts 20% of skin cancer. It starts on the upper side of epidermis. Squamous cell carcinoma appears as a red lump which develops into tumors. This type of cancer usually appears on that parts of the body which are directly exposed to the sun. It includes hands, face, ears, lips and legs.
The global non-melanoma skin cancer market is categorized based on various types and by various treatment methods. Type segment comprises basal cell carcinoma and squamous cell carcinoma. Treatment segment is further sub-segmented into non-invasive treatments and chemotherapy treatment. Non-invasive treatments include laser therapy, radiotherapy, photodynamic therapy (PDT) cryotherapy and others. The chemotherapy sub-segment includes various treatment drugs for basal cell carcinoma and squamous cell carcinoma. In terms of geographic, North America dominates the global non-melanoma skin cancer market. The U.S. represents the largest market for non-melanoma skin cancer followed by Canada in North America. In Europe, France, Germany, Italy, Spain and the U.K. holds major share of non-melanoma skin cancers market. However, Asia is expected to show high growth rates in the next five years in global non-melanoma skin cancer market.
This is due to many companies constructing their manufacturing and research facilities in the region. In addition, rising awareness about skin cancer has also fueled the growth of non-melanoma skin cancer market in the region. Japan, China and India are expected to be the fastest growing non-melanoma skin cancer markets in Asia. In recent time, increasing prevalence of skin cancer is key driver of global non-melanoma skin cancer market. In addition, extensive R&D pipelines and increasing usage of combination therapies have also fueled the growth of global non-melanoma skin cancer market. However, stringent regulatory hurdles obstruct the growth of global non-melanoma skin cancer market. In addition, high risk of side-effect and complications associated with radiation therapy also impedes the growth of global non-melanoma skin cancer market. Some of the common side-effect of radiation therapy includes itchy or red skin and rashes.
Advancement in biomedical science develops opportunity for the global non-melanoma skin cancer market. Rapid product launches and increasing mergers and acquisitions between manufacturing companies are some of the major trends of global non-melanoma skin cancer market.
Key geographies evaluated in this report are:
- North America: U.S, Canada
- Europe: France, Germany, Italy, Spain, and the UK
- Eastern Europe
- CIS
- APAC: China, India, Japan, Australia, Others
- Latin America: Argentina, Brazil, Others
- Drivers, restraints, and challenges shaping the Non-Melanoma Skin Cancer market dynamics
- Latest innovations and key events in the industry
- Analysis of business strategies of the top players
- Non-Melanoma Skin Cancer market estimates and forecasts(2015 -2021)